Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Huge volume in after-market with one trade (no change) -
TIME. PRICE. #SHARES
16:00:06.............$11.3...................426,561
Foley Hoag Recognized as 2024 Law360 "Regional Powerhouse" in Massachusetts
September 19, 2024
Law360 again recognized Foley Hoag LLP as a “Regional Powerhouse” in Massachusetts. The law firms on Law360’s list of 2024 Regional Powerhouses are driving some of the biggest deals and most high-profile courtroom battles, delivering top-tier regional expertise for clients and making a lasting impact on the law at the state and local level.
The Regional Powerhouses Series honors leading law firms in various states based on their exceptional achievements. In Massachusetts, Law360 recognized only three firms, including Foley Hoag. Law360 noted, “With some of the state's household-name clients under its belt and a former Massachusetts attorney general on its roster, Foley Hoag LLP is one of the state's premier law firms in a number of growing sectors.”
The recognition reflects the complex legal work performed for clients by Foley Hoag across cutting-edge industries, including life sciences, technology, energy and cannabis, and the results achieved. Law360 specifically highlighted the firm’s representations of:
Enanta Pharmaceuticals in a patent litigation involving Pfizer's antiviral COVID treatment Paxlovid.
https://www.foleyhoag.com/news-and-insights/news/2024/september/foley-hoag-recognized-as-2024-law360-regional-powerhouse-in-massachusetts/
The "proof is in the pudding". Let's hope Hoag representation will be positive for ENTA.
Again, representing the Plaintiff, Enanta:
https://foleyhoag.com/people/fiacco-barbara/
Thank you - VIn, Randy & dewophile plus others who might comment.
As you advice indicates - I plan on being patient or becoming a (mental) patient.
Sir Flo
After making a major hit in COLL, I decided to throw it all into ENTA (Las Vegas style) – possibly my last (age) roundup!
Not sure I have done my correct homework/research on this one. Two years prior I did purchase ENTA at 42 & sold at 38. From there it went to the 60’s. Now --
I’ve heard Dew’s take (which I respect) that it’s worth a minimum of 20 which includes NO clinical trials in the equation. Plus, I’m quite optimistic in a trial settlement with PFE.
Therefore, fellow investors, what is your rationale for investing in ENTA?
Dew et al,
Might it be legally possible for Phizer to purchase ENTA currently?
If so, what is ENTA worth now prior to any clinical trial results or infringement decisions/mediation? T.I.A.
Not sure this was posted -
Enanta Corporate Presentation - August 5, 2024
https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4
Positive announcements this upcoming week/month? 3 close together -
Upcoming Events and Presentations
H.C. Wainwright Annual Global Investment Conference, September 10, 2024
Baird Global Healthcare Conference, September 11, 2024
Cantor Global Healthcare Conference, September 17, 2024
Enanta plans to issue its full year and fiscal fourth quarter financial results press release on November 25, 2024.
https://finance.yahoo.com/news/enanta-pharmaceuticals-reports-financial-results-200100459.html
My personal treatment -
DP - great analytics. The Flo Foundation thanks you.
As luck/research would have it - good results come in 3's - MNTA, COLL and now, ENTA
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way? June 19, 2024
According to the last reported balance sheet, Enanta Pharmaceuticals had liabilities of US$54.6m due within 12 months, and liabilities of US$192.8m due beyond 12 months. Offsetting this, it had US$300.3m in cash and US$39.8m in receivables that were due within 12 months. So it can boast US$92.7m more liquid assets than total liabilities.
This surplus strongly suggests that Enanta Pharmaceuticals has a rock-solid balance sheet (and the debt is of no concern whatsoever). Having regard to this fact, we think its balance sheet is as strong as an ox. Simply put, the fact that Enanta Pharmaceuticals has more cash than debt is arguably a good indication that it can manage its debt safely. The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine Enanta Pharmaceuticals's ability to maintain a healthy balance sheet going forward.
Read more:
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-enta/enanta-pharmaceuticals/news/is-enanta-pharmaceuticals-nasdaqenta-using-debt-in-a-risky-w-1
The US is experiencing its largest summer Covid wave in at least two years
It may be time to dust off the face masks and air purifiers.
The US is in the midst of a significant Covid-19 wave, and when the US Centers for Disease Control and Prevention updates its wastewater dashboard on Friday, experts expect it to confirm that viral activity levels are the highest they’ve been during a summer surge since the CDC began publicly tracking such data in January 2022.
As of August 3, the CDC’s measure of national Covid viral activity in wastewater is at 9.01 and rising - just shy of the peak at 9.28 in July 2022. Before it started rising again in May, it was at 1.36.
Read more:
https://www.cnn.com/2024/08/16/health/covid-largest-summer-wave/index.html
Enanta Pharmaceuticals, Inc. v. Pfizer Inc.
Friday, August 09, 2024
367 Notice Setting or Resetting Hearing on Motion Fri 08/09 9:15 AM
ELECTRONIC NOTICE Setting Hearing on Motion296 MOTION to Compel Defendant Pfizer Inc. to Produce Documents and Provide Deposition Testimony : Motion Hearing set for September 25, 2024 at 11:30 AM in Courtroom 14 (In person only) before Magistrate Judge Jennifer C. Boal. Plaintiff Enanta Pharmaceuticals, Inc. has filed a motion to, among other things, compel Pfizer to produce an April 6, 2022 email as well as the attachments to that email. Docket No. 296. Defendant Pfizer, Inc. maintains that the email is privileged and has offered to submit the email ex parte for in camera review. See Docket No. 334 at 17. No later than August 22, 2024, Pfizer shall submit the email and attachments for in camera review. The documents must be submitted in hard copy at the Clerk's Office and marked DO NOT DOCKET, SUBMITTED FOR IN CAMERA REVIEW. (Hutchins, Aaron)
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
Inch by inch, we're getting there -
Barbara A. Fiacco - ENTA's Attorney - additional info -
She has represented leading pharmaceutical and life sciences clients in significant patent infringement lawsuits that have resulted in summary judgment or other favorable outcomes for her clients. Barbara also represents these clients in trade secret, inventorship, and technology transfer disputes as well as other commercial litigation.
Barbara is a Past President of the American Intellectual Property Law Association (AIPLA) and a Past President of the United States section of the International Association for the Protection of Intellectual Property (AIPPI-US), serving from 2019 to 2020. She has held a number of leadership roles in AIPLA and has represented this premier intellectual property law association in testimony on behalf of AIPLA before the Senate Judiciary Committee’s Subcommittee on Intellectual Property as well as in amicus briefs to the Supreme Court.
https://foleyhoag.com/people/fiacco-barbara/
FWIW - Patents Assigned to Enanta Pharmaceuticals, Inc.
Hepatitis B antiviral agents
Patent number: 12054493
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: January 7, 2021
Date of Patent: August 6, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Yao-Ling Qiu, Xuri Gao, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xiaowen Peng, Yat Sun Or
My daughter, Little FLO, found this on X August 6 -
Congratulations to members of Team Enanta for their publication in
@NatureComms
highlighting the preclinical data of EDP-235, Enanta’s 3CL protease inhibitor, in development for the treatment of #COVID-19. Thanks to everyone who made this publication possible and to first author Michael Rhodin who gives us permission to share this link.
Article Published: 01 August 2024
The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo
https://www.nature.com/articles/s41467-024-50931-8. This is the full, in-depth article - FANTASTIC!!
Thanks to biocqr for the original heads-up.
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
Associated Press Finance
Mon, Aug 5, 2024, 4:09 PM EDT
WATERTOWN, Mass. (AP) — WATERTOWN, Mass. (AP) — Enanta Pharmaceuticals Inc. (ENTA) on Monday reported a loss of $22.7 million in its fiscal third quarter.
The Watertown, Massachusetts-based company said it had a loss of $1.07 per share.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.49 per share.
The biotechnology company posted revenue of $18 million in the period, also surpassing Street forecasts. Five analysts surveyed by Zacks expected $17.3 million.
https://finance.yahoo.com/news/enanta-pharmaceuticals-fiscal-q3-earnings-200950084.html
I'm out of COLL. Made a great profit - $500+K in 14 months.
Someone else can take the reigns.
Good luck to all.
FLO
P.S. My new investment - ENTA.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Stock analysts at HC Wainwright reduced their FY2024 earnings estimates for Collegium Pharmaceutical in a research note issued on Tuesday, July 30th. HC Wainwright analyst O. Livnat now forecasts that the specialty pharmaceutical company will earn $5.61 per share for the year, down from their previous estimate of $5.65. HC Wainwright currently has a "Buy" rating and a $47.00 price target on the stock. The consensus estimate for Collegium Pharmaceutical's current full-year earnings is $5.68 per share. HC Wainwright also issued estimates for Collegium Pharmaceutical's Q4 2024 earnings at $1.51 EPS and FY2025 earnings at $5.85 EPS.
https://www.marketbeat.com/instant-alerts/nasdaq-coll-analyst-earnings-estimates-2024-08-01/
Reading between the lines -
Is ENTA in preclinical, developmental work for animal medications? Or, am I stretching it?!!
New career post excerpts:
Scientist, Toxicology
Evaluate individual and programmatic study data (anatomic pathology, clinical pathology, in-life parameters, etc.) as to the potential toxicity of experimental compounds in different animal species....
Qualifications:
DVM/PhD (strongly preferred), DVM or PhD in Toxicology, Pathology, or related health science field
Solid foundation in animal and/or biomedical sciences, including toxicology, pathology, and physiology with proficient knowledge of developmental and reproductive biology
https://theapplicantmanager.com/jobs?pos=ET974
No analysts' reports, as yet. Yesterday 3/6 congratulated COLL on their acquisition.
BTW - sold 90% of my COLL last week before the uptick. However, made a $560K COLL profit in the less than 14 months. Took most of the funds & bought ENTA - thank you DEW!
COLL is down 7% as I’m typing....
COLL is now UP - $4.51 Probably due to IRONSHORE's delayed release formula. .
Monday, July 29, 2024 6:10:19 AM
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
July 29, 2024
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) –
– H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year –
– Transaction Expected to be Immediately Accretive to Adjusted EBITDA –
– Acquisition Funded by Collegium’s Cash on Hand and New Five-Year Financing with Significantly Improved
Terms –
– Collegium Estimates Q2’24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms 2024
Financial Guidance for the Current Business –
– Conference Call Scheduled for Today at 8:30 a.m. ET –
STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive agreement pursuant to which Collegium will acquire Ironshore for $525 million in cash with the potential for an additional $25 million commercial milestone payment.
Ironshore is a privately held, pharmaceutical company that markets and distributes Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant prescription medicine for the treatment of attention deficit hyperactivity disorder (ADHD) in people six years of age and older and the only stimulant medication that is dosed in the evening. The acquisition of Ironshore will represent a significant milestone in advancing Collegium’s mission of building a leading, diversified specialty pharmaceutical company by expanding the Company’s business beyond pain management and establishing a commercial presence in a new and growing market.
“The Ironshore acquisition is a unique opportunity to deliver a transaction that is immediately accretive to Collegium while meeting all of our strategic objectives through the addition of a growing commercial asset that diversifies our portfolio, has significant revenue potential and exclusivity into the 2030s,” said Michael Heffernan, Chairman and Interim President and Chief Executive Officer of Collegium. “The addition of Jornay PM will establish a new presence for Collegium in ADHD, a large and growing market, where we can leverage our core commercial competencies and proven commercial execution capabilities to maximize the brand’s potential. Our healthy balance sheet and strong financial position enabled us to secure attractive financing for the transaction with terms that reduce our cost of capital and enhance our flexibility in the management of our debt.”
“We are pleased to announce this transaction with Collegium, which recognizes the value of Jornay PM and the success of Ironshore’s talented team in the delivery of an important and differentiated treatment option for patients with ADHD and their caregivers,” said Stephanie Read, Chief Executive Officer of Ironshore. “Our team has worked tirelessly to bring Jornay PM to the ADHD community and we are excited that Collegium recognizes Jornay PM’s long-term potential and is committed to supporting its continued growth.”
Transaction Rationale
Strategically aligns with Collegium’s mission of building a leading, diversified specialty pharmaceutical company by broadening the commercial portfolio beyond pain management and establishing a commercial presence in neurology via the large and growing ADHD market.
Jornay PM is poised to become Collegium’s leading growth driver. Net revenue for Jornay PM is expected to be in excess of $100 million in 2024. In the first half of 2024, Jornay PM prescriptions grew 32% year-over-year. For the full-year 2023, the product generated approximately 490,000 prescriptions, a 58% increase compared to 2022. Jornay PM is a highly differentiated treatment for ADHD due to its evening dosing, smooth therapeutic effect and dose-dependent duration.
Jornay PM is supported by 16 Orange Book-listed patents, with expiries in 2032.
Further strengthens Collegium’s financial position through an increased revenue base, expected immediate accretion to adjusted EBITDA and accelerated cash flow generation.
Additional Transaction Details
Under the terms of the agreement, Collegium will acquire all the outstanding shares of Ironshore for $525 million in cash at closing. Collegium will also pay Ironshore shareholders $25 million in additional consideration if Jornay PM net revenue exceeds a defined threshold in 2025.
The all-cash consideration will be funded by a combination of Collegium’s existing cash on hand and a $646 million secured financing from funds managed by Pharmakon Advisors, LP (Pharmakon). The new five-year term loan will replace the existing Collegium term loan from Pharmakon and reduce the interest rate by 300 basis points.
At year-end 2024, Collegium expects net leverage to be less than two times based on estimated 2024 pro forma combined adjusted EBITDA.
Collegium expects this transaction to be immediately accretive to adjusted EBITDA, excluding transaction costs.
Timing to Close
The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close in the third quarter of 2024, subject to customary closing conditions, including receipt of required regulatory approvals.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-acquire-ironshore-therapeutics-expanding-neurology
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
July 29, 2024
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) –
– H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year –
– Transaction Expected to be Immediately Accretive to Adjusted EBITDA –
– Acquisition Funded by Collegium’s Cash on Hand and New Five-Year Financing with Significantly Improved
Terms –
– Collegium Estimates Q2’24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms 2024
Financial Guidance for the Current Business –
– Conference Call Scheduled for Today at 8:30 a.m. ET –
STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive agreement pursuant to which Collegium will acquire Ironshore for $525 million in cash with the potential for an additional $25 million commercial milestone payment.
Ironshore is a privately held, pharmaceutical company that markets and distributes Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant prescription medicine for the treatment of attention deficit hyperactivity disorder (ADHD) in people six years of age and older and the only stimulant medication that is dosed in the evening. The acquisition of Ironshore will represent a significant milestone in advancing Collegium’s mission of building a leading, diversified specialty pharmaceutical company by expanding the Company’s business beyond pain management and establishing a commercial presence in a new and growing market.
“The Ironshore acquisition is a unique opportunity to deliver a transaction that is immediately accretive to Collegium while meeting all of our strategic objectives through the addition of a growing commercial asset that diversifies our portfolio, has significant revenue potential and exclusivity into the 2030s,” said Michael Heffernan, Chairman and Interim President and Chief Executive Officer of Collegium. “The addition of Jornay PM will establish a new presence for Collegium in ADHD, a large and growing market, where we can leverage our core commercial competencies and proven commercial execution capabilities to maximize the brand’s potential. Our healthy balance sheet and strong financial position enabled us to secure attractive financing for the transaction with terms that reduce our cost of capital and enhance our flexibility in the management of our debt.”
“We are pleased to announce this transaction with Collegium, which recognizes the value of Jornay PM and the success of Ironshore’s talented team in the delivery of an important and differentiated treatment option for patients with ADHD and their caregivers,” said Stephanie Read, Chief Executive Officer of Ironshore. “Our team has worked tirelessly to bring Jornay PM to the ADHD community and we are excited that Collegium recognizes Jornay PM’s long-term potential and is committed to supporting its continued growth.”
Transaction Rationale
Strategically aligns with Collegium’s mission of building a leading, diversified specialty pharmaceutical company by broadening the commercial portfolio beyond pain management and establishing a commercial presence in neurology via the large and growing ADHD market.
Jornay PM is poised to become Collegium’s leading growth driver. Net revenue for Jornay PM is expected to be in excess of $100 million in 2024. In the first half of 2024, Jornay PM prescriptions grew 32% year-over-year. For the full-year 2023, the product generated approximately 490,000 prescriptions, a 58% increase compared to 2022. Jornay PM is a highly differentiated treatment for ADHD due to its evening dosing, smooth therapeutic effect and dose-dependent duration.
Jornay PM is supported by 16 Orange Book-listed patents, with expiries in 2032.
Further strengthens Collegium’s financial position through an increased revenue base, expected immediate accretion to adjusted EBITDA and accelerated cash flow generation.
Additional Transaction Details
Under the terms of the agreement, Collegium will acquire all the outstanding shares of Ironshore for $525 million in cash at closing. Collegium will also pay Ironshore shareholders $25 million in additional consideration if Jornay PM net revenue exceeds a defined threshold in 2025.
The all-cash consideration will be funded by a combination of Collegium’s existing cash on hand and a $646 million secured financing from funds managed by Pharmakon Advisors, LP (Pharmakon). The new five-year term loan will replace the existing Collegium term loan from Pharmakon and reduce the interest rate by 300 basis points.
At year-end 2024, Collegium expects net leverage to be less than two times based on estimated 2024 pro forma combined adjusted EBITDA.
Collegium expects this transaction to be immediately accretive to adjusted EBITDA, excluding transaction costs.
Timing to Close
The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close in the third quarter of 2024, subject to customary closing conditions, including receipt of required regulatory approvals.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-acquire-ironshore-therapeutics-expanding-neurology
FWIW -
It still is a big IF that ENTA wins summary judgment against PFIZER. Even a mediated settlement is quite positive.
Back in June of 2022, RBC Capital Markets analyst Brian Abrahams states -
"A typical royalty rate might be in the 6% range, which on sales of Paxlovid's magnitude, could be more than $1 billion annually in its peak years and may speak to why it might be worth Enanta's time and expenses to pursue this," he said in a report to clients.
https://www.investors.com/news/technology/enta-stock-launches-as-enanta-causes-a-kerfuffle-for-pfizer-paxlovid/
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2024 financial results after the market closes on Thursday, August 8, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-report-second-quarter-2024-financial-results-august-8
From BIOWORLD -
Infection
Enanta Pharmaceuticals describes new PL-pro
July 22, 2024
Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections. [Subscription needed]
https://www.bioworld.com/articles/710689-enanta-pharmaceuticals-describes-new-pl-pro?v=preview
FWIW -
Friday, July 19, 2024 - A possible WIN for ENTA?
Reply to Response to Motion Fri 07/19 4:10 PM
SEALED REPLY in Support of 296 MOTION to Compel Defendant Pfizer Inc. to Produce Documents and Provide Deposition Testimony filed by Enanta Pharmaceuticals, Inc..(Cook, Savannah)
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
What has peeked my interest is the after-market trading. Approximately 2 weeks ago, I started accumulating shares en masse due to the fact that 100K- 300K+ additional shares were being traded in the after hours. Not sure if this has anything to do with the uptrend. However, psychologically - remember approximately 3 years ago the stock was $100+ PPS. Something very positive is happening - legal, clinical trials, M & A (with the new attorney on board) & the FLO Foundation is riding the wave!
https://www.nasdaq.com/market-activity/stocks/enta/after-hours
IMHO - all these patents would be a significant value incentive for a merger or a buyout -
As of June 25, 2024 -
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Type: Grant
Filed: December 2, 2022
Date of Patent: June 25, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
https://patents.justia.com/patent/12018017
A series of studies using ASK1-deficient mice have indicated that ASK1 plays important roles in many stress-related diseases, including cardiovascular and neurodegenerative diseases, suggesting that small compounds that inhibit ASK1 activity could possibly be used for the amelioration of the development and/or progression of these diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491083/
O/T ----
We need some LEVITY here. One of my favorite movie scenes.
Might as well continue to list patents as they are granted. Who know what leverage they'll have in a potential acquisition or merger?
Hepatitis B antiviral agents
Patent number: 12011425
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: January 25, 2023
Date of Patent: June 18, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Yao-Ling Qiu, Xuri Gao, Jorden Kass, Hui Cao, Wei Li, Xiaowen Peng, Byung-Chul Suh, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
FWIW - Addendum - Barbara Fiacco - ENTA, if only -
Represented Dana-Farber as lead counsel in second case against Bristol-Myers Squibb and Ono Pharmaceuticals, asserting claims for unjust enrichment and unfair competition for depriving Dana-Farber of its co-ownership rights under eight patents directed to cancer immunotherapy. On the eve of trial, in the face of Dana-Farber’s claim for hundreds of millions of dollars in damages, Defendants settled, making a substantial lump sum payment to Dana-Farber and agreeing to make potential additional payments, contingent on future events.
https://foleyhoag.com/people/fiacco-barbara/#Experience
ENTA has an outstanding litigator in their representation - Barbara Fiacco
Quote - The following Foley Hoag partners were also recognized for excellence in the industry in the following jurisdictions, and were described by IAM as:
Barbara Fiacco (National) and Donald Ware (MA) ranked in the Gold tier for litigation.
“Two of the most high-quality trial lawyers Boston has to offer,” and “A formidable team in life sciences litigation, securing multiple victories for the Dana-Farber Cancer Institute, resulting in significant payouts as well as co-ownership of groundbreaking cancer treatment patents.”
https://foleyhoag.com/news-and-insights/news/2024/june/foley-hoag-10-partners-recognized-in-2024-edition-of-iam-patent-1000/
https://foleyhoag.com/people/fiacco-barbara/
Here's the latest. Appears that ENTA is progressing well as of June 13. Comments?
https://www.pacermonitor.com/public/case/44980990/Enanta_Pharmaceuticals,_Inc_v_Pfizer_Inc
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
June 13, 2024
STOUGHTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June 27, 2025, to July 3, 2026. FDA’s grant of pediatric exclusivity now extends exclusivity of the Nucynta Franchise an additional six months, to January 3, 2027, for Nucynta and December 27, 2025, for Nucynta ER.
“We are pleased with FDA’s grant of pediatric exclusivity for the Nucynta Franchise,” said Thomas Smith, M.D., Collegium’s Chief Medical Officer. “This grant of pediatric exclusivity enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of people living with serious medical conditions and the communities we serve.”
Nucynta is currently approved in the U.S. for the management of acute pain severe enough to require an opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative treatments are inadequate in adults and pediatric patients aged six years and older with a body weight of at least 40 kg.
Nucynta ER is currently approved in the U.S. for the management of severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic, in light of the known risks associated with opioid analgesic use, and for which alternative treatment options are inadequate, and severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate.
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-obtains-six-month-extension-us-pediatric-exclusivity
Two more for the books -
Patent number: 12006291
Abstract: The present invention relates to processes for preparing a Compound (1): or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.
Type: Grant
Filed: January 10, 2023
Date of Patent: June 11, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Kaicheng Zhu, Tao Wang, Jiajun Zhang, Hui Cao, Ruichao Shen, Guoqiang Wang, George G. Wu, Yat Sun Or
Antiviral heterocyclic compounds
Patent number: 12006326
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: August 24, 2022
Date of Patent: June 11, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
June 11, 2024
Enanta Pharmaceuticals gets grant for macrocyclic compounds inhibiting coronavirus replication
....the patent outlines methods for treating viral infections, particularly coronavirus infections, by administering the disclosed compound. The methods include oral, subcutaneous, intravenous, or inhalation administration of the compound. Additionally, the patent covers inhibiting viral 3C protease or viral 3CL protease in a subject by administering the compound. The patent specifies the treatment of various strains of coronaviruses, including 229E, NL63, OC43, HKU1, SARS-CoV, and MERS coronavirus, highlighting the broad spectrum of antiviral activity claimed in the patent.
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-macrocyclic-compounds-inhibiting-coronavirus-replication/
Management has already stated such. However, it's still positive to see the following in print -
The company has now completed a majority of its multi-year payer contracts at significantly higher margins to COLL. To underscore this development and what the market is missing, if COLL were to run its business as-is and retire its debt, we estimate it could have a $1 billion net cash position by 2027. Furthermore, if their largest potential competitor (Teva Pharmaceuticals) stays out of the market, it could produce another $1 billion of free cash flow over the next three years. The current market capitalization is roughly $1 billion…”
https://finance.yahoo.com/news/collegium-pharmaceutical-inc-nasdaq-coll-211603220.html
Jefferies upgrades Collegium to buy, cites upside related to LOEs -
Jun. 07, 2024 12:13 PM ET
Jefferies upgraded Collegium (NASDAQ:COLL) to buy, stating it believes the upside potential related to upcoming losses of market exclusivity for Collegium's drugs Nucynta and Belbuca is underappreciated.
The investment bank said it sees several drivers for the drugs despite the LOEs, including a Nucynta partnership with Hikma, pediatric extensions for Nucynta, and uncertainty about Teva's launch of a generic version of Belbuca. It also believes 2024 EBITDA consensus is “too low.”
Jeffries also noted that the company’s cash generation was “significant,” with its net cash expected to eclipse its market cap in fiscal 2028. It added that the company “could likely take itself private in the 2028 timeframe.”
Jefferies set its price target for the stock at $44.
https://seekingalpha.com/news/4114181-jefferies-upgrades-collegium-to-buy-cites-upside-related-to-loes?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain
Jefferies upgrades Collegium to buy, cites upside related to LOEs -
Jun. 07, 2024 12:13 PM ET
Jefferies upgraded Collegium (NASDAQ:COLL) to buy, stating it believes the upside potential related to upcoming losses of market exclusivity for Collegium's drugs Nucynta and Belbuca is underappreciated.
The investment bank said it sees several drivers for the drugs despite the LOEs, including a Nucynta partnership with Hikma, pediatric extensions for Nucynta, and uncertainty about Teva's launch of a generic version of Belbuca. It also believes 2024 EBITDA consensus is “too low.”
Jeffries also noted that the company’s cash generation was “significant,” with its net cash expected to eclipse its market cap in fiscal 2028. It added that the company “could likely take itself private in the 2028 timeframe.”
Jefferies set its price target for the stock at $44.
https://seekingalpha.com/news/4114181-jefferies-upgrades-collegium-to-buy-cites-upside-related-to-loes?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain
Summary judgment hearing for whom?